Union Therapeutics recruits first psoriasis patient for phase IIb study

Biotech company Union Therapeutics is now testing its psoriasis treatment orismilast in an orally administered version. It is also testing the drug in a rare indication called hidradenitis suppurativa and atopic eczema.

Photo: Union Therapeutics / PR

Union Therapeutics is attempting to find the perfect dosage of drug candidate orismilast in a phase IIb study of psoriasis patients.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs